ALKS JPM Presentation 2026 FINAL.pdf

1、Alkermes 2026:Driving Profitable Growth in Neuroscience and Leading Orexin InnovationJanuary 2026 2026 Alkermes.All rights reserved.2Forward-Looking StatementsCertain statements set forth in this presentation constitute“forward-looking statements”within the meaning of the Private Securities Litigati

2、on Reform Act of 1995,as amended,including,but not limited to,statements concerning:Alkermes plcs(the“Company”or“Alkermes)expectations with respect to its current and future financial and operating performance,business plans or prospects,including its expected opportunities for growth and value crea

3、tion and expectations of profitability;the potential therapeutic and commercial value of the Companys marketed products and development candidates and expectations regarding potential opportunities and competitive positioning for the orexin 2 receptor agonist class in sleep medicine and other diseas

4、e areas;expectations regarding the timing and anticipated benefits of the planned acquisition of Avadel Pharmaceuticals plc(“Avadel”)and the potential combined organizations future operating performance;expectations regarding the patent life of LUMRYZTM;the Companys plans and expectations regarding

5、clinical development activities and strategy,including expansion and advancement of its pipeline,and anticipated timelines and study designs for the development programs for alixorexton,ALKS 4510,ALKS 7290,and the Companys other development candidates.The Company cautions that forward-looking statem

6、ents are inherently uncertain.The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk.Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to var